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pt received August 21, 20he purpose of this study was to determine whether elevated lipoprotein(a) levels and corresponding LPA risk
genotypes (rs10455872, rs3798220, kringle IV type 2 repeat polymorphism) prospectively associate with increased
risk of aortic valve stenosis (AVS).Background The etiologic basis of AVS is unclear. Recent data implicate an LPA genetic variant (rs10455872), associated with
Lp(a) levels, in calciﬁc AVS.Methods We combined data from 2 prospective general population studies, the Copenhagen City Heart Study (1991 to 2011;
n ¼ 10,803) and the Copenhagen General Population Study (2003 to 2011; n ¼ 66,877), following up 77,680
Danish participants for as long as 20 years, during which time 454 were diagnosed with AVS. We conducted
observational and genetic instrumental variable analyses in a Mendelian randomization study design.Results Elevated Lp(a) levels were associated with multivariable adjusted hazard ratios for AVS of 1.2 (95% conﬁdence
interval [CI]: 0.8 to 1.7) for 22nd to 66th percentile levels (5 to 19 mg/dl), 1.6 (95% CI: 1.1 to 2.4) for 67th to 89th
percentile levels (20 to 64 mg/dl), 2.0 (95% CI: 1.2 to 3.4) for 90th to 95th percentile levels (65 to 90 mg/dl), and
2.9 (95% CI: 1.8 to 4.9) for levels greater than 95th percentile (>90 mg/dl), versus levels less than the 22nd
percentile (<5 mg/dl; trend, p < 0.001). Lp(a) levels were elevated among carriers of rs10455872 and rs3798220
minor alleles, and of low number of KIV-2 repeats (trend, all p < 0.001). Combining all genotypes, instrumental
variable analysis yielded a genetic relative risk for AVS of 1.6 (95% CI: 1.2 to 2.1) for a 10-fold Lp(a) increase,
comparable to the observational hazard ratio of 1.4 (95% CI: 1.2 to 1.7) for a 10-fold increase in Lp(a) plasma levels.Conclusions Elevated Lp(a) levels and corresponding genotypes were associated with increased risk of AVS in the general
population, with levels >90 mg/dl predicting a threefold increased risk. (J Am Coll Cardiol 2014;63:470–7)
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cardiovascular disease (1–4). Recently, a genome-wide asso-
ciation study has identiﬁed a genetic variant (rs10455872
SNP) in the LPA gene locus, determining plasma levels of
Lp(a), as associated with aortic valve calcium and aortic valve
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13; accepted September 7, 2013.Calciﬁc AVS represents the most common heart valve
condition requiring treatment among adults in Western
societies (6). It is estimated to affect 2% to 7% of the pop-ulation more than 65 years of age (7). Previously considered
a passive, degenerative condition in which the valve degen-
erates with age in association with calcium accumulation,
it is increasingly clear that disease progression is a regulated
process that shares risk factors with atherosclerotic
cardiovascular disease, including elevated cholesterol levels,
hypertension, smoking, and diabetes mellitus (8–10). In
addition, congenital malformations of the aortic valve, such
as bicuspid valve morphology, possibly present in w50% of
patients with severe AVS, represent important risk factors
(11). However, at present, and despite some shared risk
factors with atherosclerotic disease, no means to effectively
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471prevent aortic valve disease progression exists, and aortic
valve replacement, costly and associated with perioperative
mortality, remains the only treatment option (5,7). It is
hoped that identiﬁcation of causal risk factors may open
opportunities for prevention.
Lp(a) consists of a cholesterol-laden low-density lipo-
protein particle bound to a plasminogenlike glycoprotein,
apolipoprotein(a) (12). Lp(a) promotes atherosclerotic
stenosis, and possibly thrombosis, and has been hypothe-
sized to contribute to wound healing (3,13–16), each of
which could explain an association with AVS. Plasma levels
of Lp(a) are primarily genetically determined by variation in
the LPA gene coding for apolipoprotein(a) (12). Variation in
the LPA gene includes the kringle IV type 2 (KIV-2) repeat
polymorphism, determining the size of the expressed apo-
lipoprotein(a), the size of which correlates inversely with
Lp(a) levels (1,12). Two single nucleotide polymorphisms
(SNPs), rs10455872 and rs3798220 tagging the KIV-2
polymorphism, also strongly associate with Lp(a) levels (2).
In the present study, we tested the hypothesis that
elevated Lp(a) levels and corresponding LPA risk genotypes
(low number of KIV-2 repeats, rs10455872 carriers,
rs3798220 carriers) prospectively associate with increased
risk of AVS in the general population. We assessed genetic
evidence by conducting instrumental variable analysis in
a Mendelian randomization study design (17). For these
purposes, we combined data from 2 large prospective studies
of the Danish general population, the CCHS (Copenhagen
City Heart Study) and the CGPS (Copenhagen General
Population Study), with baseline information on Lp(a) levels
and LPA KIV-2 repeat, rs10455872, and rs3798220
genotypes.Methods
Participants. The CCHS is a general population study
initiated in 1976 to 1978 with follow-up examinations in
1981 to 1983, 1991 to 1994, and 2001 to 2003 (18).
Participants were randomly selected from the Copenhagen
Civil Registration System to reﬂect the general population of
Copenhagen ages 20 to 100 years. Examinations included
a self-administered questionnaire, reviewed by an investi-
gator on the day of attendance, a physical examination, and
blood sampling. Smokers were active smokers, and diabetes
mellitus was deﬁned as self-reported disease, use of insulin
or oral hypoglycemic drugs, and/or a nonfasting plasma
glucose of >11 mmol/l. For the present study, we included
all CCHS participants of Danish descent with no prior
history of AVS, and with an available Lp(a) measurement
performed shortly after sampling: 9,647 from the 1991 to
1994 examination (16,563 invited, 61% response rate) and
an additional 1,156 from the 2001 to 2003 examination
(12,599 invited, 50% response rate). A blood sample for
deoxyribonucleic acid analysis was available for a total of 10,359
included participants. Among included 1991 to 1994 partici-
pants, 4,629 also had Lp(a) measurements performed at the2001 to 2003 examination, allow-
ing correction for regression dilu-
tion bias (19).
The CGPS is a Danish general
population study initiated in
2003 and still recruiting (45%
response rate) (20). Participants
of Danish descent were randomly
selected from the Copenhagen
Civil Registration System to
represent the population of the greater Copenhagen area ages
20 to 100 years. Data collection in this study is almost
identical to that of the CCHS. For the present study, we
included all participants of Danish descent without prior
history of AVS, and with an available LPA rs10455872,
rs3798220, or KIV-2 genotype, and/or an available Lp(a)
measurement (n ¼ 66,877). Among included participants,
LPA rs10455872 genotypes were available on 66,780
(recruited 2003 to 2010), rs3798220 genotypes on 66,803
(recruited 2003 to 2010), KIV-2 genotypes on 29,347
participants (recruited 2003 to 2006), and Lp(a) measure-
ments on 18,213 participants (recruited 2003 to 2005).
We followed up all CCHS and CGPS participants from
time of study inclusion and censored at the occurrence of
AVS (n ¼ 454), death (n ¼ 6,632), emigration (n ¼ 364), or
May 2011, whichever came ﬁrst. Follow-up was 100%
complete; that is, we did not lose track of a single person
during follow-up.
Information on diagnoses of AVS (International Clas-
siﬁcation of Diseases-Eighth Edition [ICD-8], codes
424.10, 424.12, 424.18, 424.19; and 10th edition [ICD-
10], codes I35.0 and I35.2) were ascertained from the
national Danish Patient Registry, and the national Danish
Causes of Death Registry, public registers to which all
hospitalizations and deaths in Denmark have been reported
since 1977. Similarly, information on diagnoses of
myocardial infarction (ICD-8 code 410; and ICD-10 codes
I21 to I22) and congenital aortic valve malformations
(ICD-8 codes 746.62, 746.89, 746.99, and 747.29; and
ICD-10 codes Q23.0, Q23.1, Q23.8, and Q23.9) were
ascertained from these registries for all participants. Among
persons with a diagnosis of AVS, information on aortic
valve replacement were ascertained from national classiﬁ-
cations of surgical procedures (surgery and treatment
procedures from 1971 to 1995, codes 30780, 30810,
31268, 31269; and SKS surgery procedures codes
KFMD00 to KFMD20 and KFMD96) administered by
the Danish National Board of Health.
The CCHS and the CGPS were approved by Herlev
Hospital and by a Danish ethical committee, and were
conducted according to the Declaration of Helsinki.
Participants gave written informed consent.
Laboratory analysis. At the 1991 to 1994 CCHS exami-
nation, Lp(a) total mass was measured using a well-validated
in-house assay, as described previously (21). At the 2001 to
2003 CCHS examination and for the ﬁrst 5,576 CGPS
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472measurements in 2003 to 2004, Lp(a) total mass was
measured immediately after sampling using a sensitive
immunoturbidimetric assay from DiaSys (DiaSys Diagnostic
Systems, Holzheim, Germany), as described previously (21).
An additional 12,637 Lp(a) total mass measurements were
performed in 2011 on thawed samples from CGPS partic-
ipants recruited in 2004 to 2005, and using a well-validated
latex-enhanced immunoturbidimetric assay from Denka
Seiken (Denka Seiken, Tokyo, Japan). Enzymatic assays
were used on fresh samples to measure plasma levels of total
cholesterol, high-density lipoprotein cholesterol, and apoli-
poprotein B. The LPA KIV-2 repeat polymorphism was
genotyped by real-time polymerase chain reaction analysis
yielding an estimate of the sum of repeats on both alleles, as
described previously (1). Genotyping for LPA rs3798220
and rs10455872 SNPs was performed by TaqMan (Applied
Biosystems, Foster City, California) analysis. Genotype
distributions did not differ from those predicted by the
Hardy-Weinberg equilibrium.
Statistical analysis. We used Stata SE 12.1 (StataCorp.,
College Station, Texas). One-way analysis of variance was
used to estimate the contribution of LPA KIV-2,
rs10455872, and rs10455872 genotypes to the variation in
plasma Lp(a) levels (levels were square root transformed
because of skewedness of the distribution).
For further analyses, participants were divided into groups
based on percentiles of the Lp(a) concentration distribution,
as done previously (where 5 mg/dl, corresponding to the
22nd percentile, represents the detection limit of our in-
house assay) (1,21), or based on corresponding LPA KIV-
2 percentiles, or on LPA rs10455872 and rs3758220
carrier status. To avoid potential bias from use of different
Lp(a) assays (although comparable [21]), Lp(a) percentile
groups were deﬁned separately for each assay and then
combined. Lp(a) cutpoints in mg/dl, corresponding to
percentile cutpoints, are based on fresh sample Denka
Seiken measurements (n ¼ 22,000), a widely available
commercial assay. Cuzick nonparametric test for trend was
used to test for differences in Lp(a) levels between different
LPA genotype combinations. Cox regression was used to
estimate hazard ratios of incident AVS with 95% conﬁdence
intervals (CIs). We analyzed age at event using left-
truncation (delayed entry), and age as time scale. Analyses
were age and sex adjusted, or multivariable additionally
adjusted for total cholesterol, high-density lipoprotein
cholesterol, systolic blood pressure, smoking, and diabetes
mellitus. Information on additional covariates was w99%
complete; the few persons who lacked information on
covariates were excluded from multivariable adjusted anal-
yses. Total cholesterol values were adjusted for the Lp(a)
contribution, as done previously (1). Based on the second
Lp(a) measurement in 2001 to 2003, hazard ratios for
increased Lp(a) levels were corrected for regression dilution
bias (19). Proportionality of hazards over time was assessed
by plotting the cumulative hazard (on a log scale) versus
analysis time. Suspicion of nonparallel lines was furthertested using Schoenfeld residuals. No major violations of the
proportional hazards assumption were detected. Interaction
of Lp(a) levels or LPA genotypes with other covariates
including sex was evaluated by comparing models with and
without 2-factor interaction tests using maximum likelihood
ratio tests. No interactions were observed (e.g., p values for
interaction with sex ranged from 0.15 [genotypes] to 1.00
[Lp(a) levels]). Finally, to validate ﬁndings for elevated
plasma Lp(a) levels, sensitivity analyses with Cox regression
were conducted.
Instrumental variable analysis, using 3 different approaches,
was used to estimate relative risk or hazard ratio estimates of
AVS for a 10-fold increase in genetically elevated Lp(a) levels
(17). The LPA genotypes (rs10455872 genotype, rs3798220
genotype, and/or KIV-2 percentile groups) were used as
instrumental variables, that is, variables that only affect
outcome, namely, AVS, through a robust association with an
intermediary variable, namely, Lp(a), and importantly, do not
suffer from the same error terms as found in the direct associ-
ation of the intermediary variable with risk of endpoint,
including potential confounding and reverse causation. (For
a detailed description of instrumental variable analyses, please
refer to Methods in the Online Appendix.)
For comparison with instrumental variable analysis
genetic risk estimates, we calculated the observational age-
and sex-adjusted hazard ratio for AVS for a 10-fold increase
in plasma Lp(a) levels.
Results
Baseline characteristics of the 77,680 participants (all and by
lipoprotein[a] percentiles) in the combined CCHS and
CGPS are shown in Table 1. (For baseline characteristics
stratiﬁed by LPA genotypes, please refer to Online Tables 1
and 2.) We observed a total of 454 ﬁrst-time AVS events
during as much as 20 years (mean 5 years) of follow-up.
Lp(a) plasma levels and risk of aortic valve sten-
osis. Elevated Lp(a) levels associated with multivariable
adjusted hazard ratios for AVS of 1.2 (95% conﬁdence
interval [CI]: 0.8 to 1.7) for 22nd to 66th percentile levels
(5 to 19 mg/dl), 1.6 (95% CI: 1.1 to 2.4) for 67th to 89th
percentile levels (20 to 64 mg/dl), 2.0 (95% CI: 1.2 to 3.4)
for 90th to 95th percentile levels (65 to 90 mg/dl), and 2.9
(95% CI: 1.8 to 4.9) for levels more than 95th percentile
(>90 mg/dl), versus levels less than 22nd percentile (<5 mg/dl;
trend, p < 0.001) (Fig. 1). Corresponding events per 10,000
person-years were 11, 15, 18, and 24, respectively, versus 10
in the reference group.
In sensitivity analyses, we observed similar risk estimates
in women and men separately (Online Fig. 1), when
considering only AVS events resulting in aortic valve
replacement (Online Fig. 2), when considering only AVS
events recorded with recent ICD-10 coding (Online Fig. 3),
when including only participants free of myocardial infarc-
tion (Online Fig. 4) or adjusting for such (Online Fig. 5), or
when excluding participants diagnosed with congenital
Table 1 Baseline Characteristics of Participants at Study Entry
All
Lp(a) Percentiles
<22nd
(<5 mg/dl)
22nd–66th
(5–19 mg/dl)
67th–89th
(20–64 mg/dl)
90th–95th
(65–90 mg/dl)
>95th
(>90 mg/dl)
n 77,680 6,123 13,053 6,677 1,728 1,435
Women, % 56 51 55 55 58 62
Age, yrs 58 (47–67) 58 (47–68) 58 (47–68) 59 (48–69) 59 (48–69) 59 (50–69)
Total cholesterol, mg/dl 216 (189–247) 216 (185–247) 220 (193–251) 224 (197–255) 236 (205–263) 239 (212–274)
HDL cholesterol, mg/dl 62 (46–73) 62 (46–73) 58 (46–73) 62 (50–73) 62 (50–77) 62 (50–73)
Systolic BP, mm Hg 138 (125–152) 138 (124–152) 137 (124–152) 137 (125–152) 140 (125–155) 140 (125–155)
Smoking, % 24 35 34 33 34 34
Diabetes mellitus, % 4 5 4 4 5 5
Lp(a), mg/dl 14 (6–35) 3 (2–4) 11 (7–17) 40 (30–51) 80 (63–95) 124 (104–148)
LPA rs10455872, % carriers 14 1 1 31 59 45
LPA rs3798220, % carriers 2 2 1 1 6 24
LPA KIV-2, no. of repeats 36 (30–41) 38 (34–43) 37 (33–42) 33 (28–38) 28 (25–32) 27 (22–31)
Values are n, %, or median (interquartile range). Lp(a) levels were measured in 29,016 persons. To convert cholesterol (total and HDL) to mmol/l, multiply values by 0.0259.
BP ¼ blood pressure; HDL ¼ high density lipoprotein.
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473aortic valve malformations (Online Fig. 6). In analyses
conducted separately for the CCHS and the CGPS, risk
estimates were most pronounced in the CCHS with the
longest follow-up (Online Fig. 7). For comparison with
ﬁndings for Lp(a) levels, we evaluated risk of AVS as
a function of apolipoprotein B quintiles or extreme levels
and found no association (Online Figs. 8 and 9).
Genotypes and Lp(a) levels. In accordance with previous
ﬁndings (2), median Lp(a) levels were 11 mg/dl, 60 mg/dl,
and 108 mg/dl (trend, p < 0.001), respectively, for
rs10455872 noncarriers, heterozygotes, and homozygotes,
and correspondingly for rs3798220, 14 mg/dl, 95 mg/dl, and
133 mg/dl (trend, p < 0.001). Also, Lp(a) levels increased
with decreasing numbers of LPA KIV-2 repeats: 8 mg/dl,
12 mg/dl, 23 mg/dl, 49 mg/dl, and 65 mg/dl (trend,Figure 1 Risk of Aortic Valve Stenosis as Function of Elevated Lp(a)
Analyses were adjusted for (left) age and sex or (right) multivariable adjusted additional
smoking, and diabetes mellitus. Lp(a) in mg/dl is shown as median (interquartile range).p < 0.001), respectively, for number of KIV-2 repeats
greater than the 79th percentile, between the 35th and 79th
percentile, the 12th and 34th percentile, the sixth and 11th
percentile, and less than the sixth percentile.
The rs10455872 genotype explained 28% of the total
variation in plasma Lp(a) levels, the rs3798220 genotype
explained 5%, and the KIV-2 genotype explained 24%.
Combined, the genotypes explained 41% of the total varia-
tion in plasma Lp(a) levels. Carriers of rs10455872 and
rs3798220 minor alleles had increased levels of Lp(a) across
all categories of KIV-2 repeats (trend, p ¼ 0.04 to
p < 0.001), and Lp(a) levels increased with decreasing
numbers of KIV-2 repeats across all rs10455872 and
rs3798220 genotype categories (trend, all p< 0.001) (Fig. 2).
Figure 2 demonstrates that although the genotypes are notLevels
ly for total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure,
CI ¼ conﬁdence interval.
Figure 2 Median Lp(a) Levels as Function of LPA Genotype
The LPA KIV-2 genotype is displayed as percentile cutpoints of number of repeats.
The LPA single nucleotide polymorphism (SNP) genotypes are displayed as
noncarriers of both SNPs, carriers of only rs10455872 (including heterozygotes
and homozygotes), carriers of only rs3798220 (including heterozygotes and
homozygotes), and carriers of both SNPs (including heterozygotes and homozy-
gotes for each SNP). The p values denote (left) test for trend of Lp(a) levels across
KIV-2 percentile groups stratiﬁed on SNP genotypes, and (right) test for trend of
Lp(a) levels across SNP genotypes stratiﬁed on KIV-2 percentile groups.
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474independent and that SNP carrier status is known to tag
a relatively low number of KIV-2 repeats (2), all genotypes
contribute independent information, for example, for a given
number of KIV-2 repeats, SNPs associate independently
with Lp(a) levels, and vice versa.
Genotypes and risk of aortic valve stenosis. Carriers of
rs10455872 minor alleles were at increased risk of AVS with
multivariable adjusted hazard ratios of 1.6 (95% CI: 1.2 to
2.0) and 1.5 (95% CI: 0.5 to 4.8) for heterozygotes and
homozygotes as compared to noncarriers (trend, p < 0.001)
(Fig. 3). Corresponding events per 10,000 person-years were
15 and 13, versus 10 in noncarriers. We found no increased
risk of AVS in carriers of rs3798220 minor alleles with
a hazard ratio of 1.0 (95% CI: 0.5 to 1.8) for heterozygotes
as compared to noncarriers. Corresponding events per
10,000 person-years were 10 and 11. No homozygotes
experienced an event. Finally, we found a trend toward
increased risk of AVS for low number of KIV-2 repeats
with, for example, hazard ratios of 1.1 (95% CI: 0.7 to 1.8)
and 1.5 (95% CI: 0.9 to 2.3) for number of KIV-2 repeats
between the sixth and 11th percentile, and less than sixth
percentile, as compared to number of repeats more than 79th
percentile (trend, p ¼ 0.06). Corresponding events per
10,000 person-years were 14 and 17, versus 13 in the
reference group.
Instrumental variable analysis, observational versus genetic
estimates. A 10-fold increase in plasma Lp(a) levels
associated with an age- and sex-adjusted hazard ratio of
AVS of 1.4 (95% CI: 1.2 to 1.7), namely, the observationalestimate (Fig. 4). In comparison, the instrumental variable
analysis estimate of the relative risk of AVS for a 10-fold
increase in genetically determined Lp(a) values was 1.6
(95% CI: 1.2 to 2.1) based on individual participant data
and including all LPA genotypes (rs10455872 genotype,
rs3798220 genotype, and KIV-2 percentile group; F-value
of 1,238). We observed similar results using a combined
genotype score or a combined extreme genotype score
approach. In analyses based on each genotype separately,
using individual participant data, only results for the
rs10455872 genotype reached statistical signiﬁcance.
Discussion
In the present prospective study of as many as 77,680
persons, we demonstrate dose-dependent increased risk of
AVS in those with elevated Lp(a) levels, a novel ﬁnding in
a general population setting. Persons with Lp(a) levels
greater than the 90th percentile thus have a twofold to
threefold increased risk of having AVS, as compared to
persons in the lower ﬁfth of the concentration distribution,
and with similar ﬁndings in women and men separately.
Further, the conﬁrmed association of LPA rs10455872
minor allele carrier status with increased risk of AVS, taken
together with our instrumental variable analysis results
including information on 3 LPA genetic variants (all asso-
ciated with lipoprotein[a] levels), indicate that the associa-
tion may be causal.
Mechanism of action. Lp(a) is an emerging risk factor for
ischemic cardiovascular disease (4,22), where data from
in vitro, animal, and large genetic studies of LPA gene
variants (1–3,13,14) provide evidence for a causal role in
promoting atherosclerotic stenosis, and possibly also
thrombosis at extreme Lp(a) levels. Lp(a) is found exclusively
in humans, apes, and Old World monkeys, and in an aber-
rant form in the hedgehog (12). Thus, Lp(a) developed twice
independently during evolution, yet the normophysiological
role of Lp(a) is unknown. A role for Lp(a) in wound healing
has been hypothesized (12,15), where Lp(a)may bind to ﬁbrin
through its apolipoprotein(a) component, possibly inhibiting
ﬁbrinolysis limiting bleeding, and may deliver cholesterol
through its low-density lipoprotein component to sites of
tissue healing. This hypothesis is supported by data demon-
strating preferential accumulation of Lp(a) at sites of tissue
injury and repair (16,23). Both Lp(a)-mediated mechanisms
involved in normophysiological phenomena such as wound
healing and in pathophysiological manifestations such as
atherosclerotic stenosis may explain an association with AVS,
considered an ongoing process of injury and tissue repair
responses, and sharing risk factors with atherosclerotic disease
(6,8,9). Incidentally, apolipoprotein (a), B, and E have been
demonstrated in early through end-stage aortic valve lesions
(but not in unaffected valves) in humans (24).
An alternative explanation for the association of
Lp(a) levels with risk of AVS, may be AVS with or
without underlying congenital malformations and resulting
Figure 3 Risk of Aortic Valve Stenosis as Function of LPA rs10455872, rs3798220, and KIV-2 Genotypes
The LPA KIV-2 genotype is displayed as percentile cutpoints of number of repeats, also shown as median (interquartile range) for number of repeats. Analyses were adjusted for
(left) age and sex or (right)multivariable adjusted additionally for total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, smoking, and diabetes mellitus.
CI ¼ conﬁdence interval.
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475post-stenotic turbulent ﬂow leading to Lp(a) elevations,
possibly also dependent on isoform size. However, AVS is
not capable of altering a person’s LPA genotype, and thus,
reverse causality can not explain the association of genotype
with AVS. Further, for the association of LPA genotypes
with risk of AVS to be confounded by, for example,
a concomitant bicuspid valve, the LPA genotypes must be
in linkage disequilibrium with genes implicated in
congenital bicuspid valve development, which to the best of
our knowledge has never been reported. Also, given the
stepwise association of LPA rs10455872 SNP and number
of KIV-2 repeats with risk of AVS, confounding of
the association by linkage disequilibrium seems highly
unlikely.
Comparison with previous studies. In support of our
general population ﬁndings, an association of elevated Lp(a)
levels with increased risk of AVS or aortic valve sclerosis,
considered a precursor of AVS (7) has been reported in
smaller case-control studies (25–27) and in an elderly pop-
ulation, where those with levels greater than the 75th
percentile were at 23% increased risk of primarily aortic valve
sclerosis as compared to those with levels less than the 25thpercentile in cross-sectional analyses (10). Recently,
a genome-wide association study has identiﬁed the LPA
rs10455872 minor allele as being associated with presence of
aortic valve calcium, a possible early phenotype for valvular
heart disease (5). Instrumental variable analysis using this
variant only, and conducted in a subset of participants,
suggested causality between elevated Lp(a) levels and aortic
valve calcium. We contributed conﬁrmatory data (i.e.,
rs10455872 genotypes in the CCHS) to this study,
demonstrating an association of rs10455872 with clinical
AVS in the CCHS (5). We now extend previous ﬁndings,
and in our combined study of the CCHS and the CGPS,
demonstrate a clear stepwise increase in risk of AVS with
increasing levels of Lp(a) in the general population. Further,
we provide genetic data using information on 3 LPA gene
variants explaining 41% of the total variation in plasma
Lp(a) levels, and demonstrating a 1.6-fold increased risk of
AVS upon a 10-fold increase in genetically elevated Lp(a)
levels; importantly, Lp(a) levels may vary 1,000-fold between
individual persons (12). Of note, the rarity of rs3798220
carrier status severely limited our ability to predict any
increased risk of AVS on the basis of this genotype alone.
Figure 4 Instrumental Variable Analysis
Observational and genetic risk estimates for aortic valve stenosis for a 10-fold increase in Lp(a) levels. CI ¼ conﬁdence interval.
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476In contrast to ﬁndings for aortic valve disease, elevated
Lp(a) levels do not seem to play a major role in coronary
artery calciﬁcation associated with low-density lipoprotein
cholesterol and apolipoprotein B levels, as demonstrated in
a recent study (28), and this may reﬂect differences in
pathobiology of valvular vs. vascular calciﬁcation. Also, we
found no association of apolipoprotein B levels with risk of
AVS.
Study limitations. We included solely white persons of
Danish descent, which may limit the generalizability of our
ﬁndings, especially as Lp(a) levels vary with ethnicity (12).
However, the uniformity of the included participants
ensures minimal risk of confounding by population
admixture, which if present, may lead to false positive
ﬁndings in instrumental variable analyses (17). Ascertain-
ment of AVS was done by ICD-8 and ICD-10 codes and
not by prospective clinical outcome data collection or by
valve imaging of all participants. A limitation of such an
approach is that, in particular, ICD-8 codes may not be
entirely speciﬁc for AVS, that AVS events may include
both calciﬁcation of a trileaﬂet valve and a congenitally
bicuspid valve as these 2 conditions may be indistinguish-
able with severe disease, and further, that participants with
less severe aortic stenosis may not have been coded ashaving AVS. However, such misclassiﬁcation of partici-
pants with or without AVS may only have resulted in an
underestimation of the true strength of the association. In
further support of the validity of our ﬁndings, sensitivity
analyses revealed similar results when only including events
leading to aortic valve replacement, when only including
events recorded with recent ICD-10 coding, when
excluding participants diagnosed with myocardial infarction
where high Lp(a) levels represent a contributing factor
(1,2), or when excluding participants diagnosed with
congenital aortic valve malformations, although likely
underdiagnosed in our general population sample. Of note,
overall participants with congenital aortic valve malforma-
tions did not have elevated Lp(a) levels (data not shown).
Conclusions
We demonstrate stepwise increases in risk of AVS with
increasing Lp(a) levels in the general population. Further, we
demonstrate association of genetic variation affecting plasma
levels of Lp(a) with risk of AVS. However, to ﬁrmly
establish whether elevated Lp(a) causes increased risk of
AVS, evidence from clinical trials of the effect of lowering
Lp(a) levels is required.
JACC Vol. 63, No. 5, 2014 Kamstrup et al.
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For supplemental methods, references, ﬁgures, and tables, please see the
online version of this article.
